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In Brief
Mathew et al. find that the Hedgehog (HH)
coreceptors GAS1, BOC, and CDON are
expressed in pancreatic cancer. Ablation
of two of these coreceptors reduces HH
responsiveness but unexpectedly in-
creases pancreatic tumor growth through
the induction of an angiogenic response.
This work uncovers a complex and previ-
ously unappreciated dose-dependent
role for HH signaling in pancreatic cancer
with potential clinical implications.
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Pancreatic cancer, a hypovascular andhighly desmo-
plastic cancer, is characterized by tumor expression
of Hedgehog (HH) ligands that signal to fibroblasts
in the surrounding stroma that in turn promote tumor
survival and growth. However, the mechanisms and
consequences of stromal HH pathway activation are
not well understood. Here, we show that the HH core-
ceptors GAS1, BOC, and CDON are expressed in
cancer-associated fibroblasts. Deletion of two core-
ceptors (Gas1 and Boc) in fibroblasts reduces HH
responsiveness. Strikingly, these fibroblasts promote
greater tumor growth in vivo that correlates with
increased tumor-associated vascularity. In contrast,
deletion of all three coreceptors (Gas1, Boc, and
Cdon) results in the near complete abrogation of HH
signaling and a corresponding failure to promote
tumorigenesis and angiogenesis. Collectively, these
data identify a role forHHdosage inpancreatic cancer
promotion and may explain the clinical failure of HH
pathway blockade as a therapeutic approach in
pancreatic cancer.INTRODUCTION
Pancreatic cancer, one of the deadliest human malignancies, is
almost invariably associated with oncogenic mutations of Kras
and the inappropriate activation of embryonic signaling path-
ways (Hruban et al., 2001; Jones et al., 2008). Pancreatic cancer
is preceded by precursor lesions, the most common of which
are pancreatic intraepithelial neoplasias (PanINs) (Klimstra
and Longnecker, 1994). Notably, tissue-specific expression of
mutant Kras in mice recapitulates the stepwise progression of
the human disease and constitutes a reasonable mouse model
of pancreatic cancer (Hingorani et al., 2003).484 Cell Reports 9, 484–494, October 23, 2014 ª2014 The AuthorsAberrant activation of Hedgehog (HH) signaling is observed in
pancreatic cancer in both humans (Berman et al., 2003; Thayer
et al., 2003) and mice (Hingorani et al., 2005). In pancreatic can-
cer, the HH pathway is proposed to act in a paracrine manner,
where epithelial tumor cells secrete HH ligands that signal to
cells of the tumor stroma (Yauch et al., 2008). HH signaling is
activated by ligand binding to the 12-pass transmembrane pro-
tein, Patched (PTCH1), which relieves an inhibitory effect on a
second, G-protein-coupled-receptor-like protein, Smoothened
(SMO) (Carpenter et al., 1998). Derepression of SMO results in
a cascade of events that ultimately leads to the activation of
GLI transcription factors and modulated target gene expression.
HH pathway components such as Ptch1 and Gli1 are direct
transcriptional targets, thus establishing a feedback loop that
regulates the level of pathway activity (Agren et al., 2004; Dai
et al., 1999).
In tumors classically associated with cell-autonomous activa-
tion of HH signaling, such as basal cell carcinoma and medullo-
blastoma, HH inhibition has emerged as a therapeutic strategy
(Molckovsky and Siu, 2008; Rudin et al., 2009). Small-molecule
inhibitors that target SMO have been successfully developed
to inhibit signaling and induce tumor regression (Rudin et al.,
2009). HH inhibitors have also been applied to tumor types
that rely on paracrine HH signaling (Yauch et al., 2008). Whereas
SMO inhibition in the clinic hasmet with initial success, the emer-
gence of drug-resistant Smo mutations in tumors (Yauch et al.,
2009) underscores the need for alternative approaches to restrict
HH pathway function.
GAS1, BOC, and CDON are cell-surface-associated proteins
that bind HH ligands and function as pathway activators (Allen
et al., 2007; Martinelli and Fan, 2007; Tenzen et al., 2006; Zhang
et al., 2006). During neural tube development, GAS1, BOC, and
CDON are required for HH signal transduction (Allen et al., 2011).
However, despite their collective requirement during HH-depen-
dent embryogenesis, the role of these proteins has not been
explored in adult tissues and organs and their potential contribu-
tion to disease, including cancer, is currently unknown.
Here, we investigated Gas1, Boc, and Cdon expression
and function in pancreatic cancer to determine whether they
constitute potential therapeutic targets. We found that all three
coreceptors were expressed in the adult pancreas and upregu-
lated in pancreatic cancer stroma.We also observed that, similar
to their role in embryogenesis, these coreceptors were required
to mediate HH signal transduction in pancreatic fibroblasts.
Counter to prevailing paradigms, whereas deletion of two core-
ceptors (Gas1 and Boc) in pancreatic fibroblasts led to reduced
HH responsiveness, this resulted in increased tumor growth.
In contrast, deletion of all three coreceptors (Gas1, Boc, and
Cdon) abrogated HH signaling and blocked tumor promotion.
Notably, the tumor-promoting effects of reduced HH signaling
were due to increased angiogenesis mediated by the tumor
stroma. These findings uncover a dosage-dependent role of
HH signaling in the regulation of tumor angiogenesis in pancre-
atic cancer.
RESULTS AND DISCUSSION
Gas1, Boc, and Cdon Are Expressed in Fibroblasts and
Stellate Cells in the Normal Adult and Neoplastic
Pancreas
Given the requirement of the HH coreceptors GAS1, BOC, and
CDON in embryonic development (Allen et al., 2011), we sought
to identify a role for these HH pathway components in adult tis-
sue. To determine ifGas1, Boc, and Cdonwere expressed in the
normal pancreas, during pancreatitis, and/or in the neoplastic
pancreas, we harvested pancreata from adult wild-type or
Ptf1aCre;LSL-KrasG12D (KC) mice (Hingorani et al., 2003). KC
pancreata were harvested 3 weeks following the induction of
acute pancreatitis using the cholecystokinin agonist caerulein;
this treatment synergizes with oncogenic Kras to drive tissue-
wide PanIN formation and the accumulation of a fibroinflamma-
tory stroma (Guerra et al., 2007; Morris et al., 2010). Wild-type
pancreata were harvested from either untreated adult animals
or from animals 1 day after caerulein treatment, at the peak of
pancreatitis. Expression of all three coreceptors, as measured
by quantitative RT-PCR (qRT-PCR) analysis, was barely detect-
able in control tissue (untreated adult pancreata) but was signif-
icantly increased in KC pancreata. In addition, we observed
a significant increase in Boc expression and a subtle increase
in Gas1 and Cdon expression in the pancreatitis samples
(Figure 1A).
To determine the cellular compartment in which these core-
ceptors are expressed, we crossed mice bearing reporter alleles
of Gas1 (Gas1LacZ/+; Martinelli and Fan, 2007) or Boc (BocPLAP/+;
Zhang et al., 2011) into the KC model of pancreatic cancer (Fig-
ure 1B). Pancreata were harvested from adult animals 3 weeks
after inducing acute pancreatitis. Analysis of control pancreata
revealed a perivascular and periductal expression pattern for
Gas1 and Boc as well as in scattered cells throughout the paren-
chyma (Figure 1B). Strikingly, in KC tissues, Gas1 and Boc
expression expanded throughout the stroma surrounding PanIN
lesions (Figure 1B).
To confirm that the qRT-PCR and reporter-allele-expression
data correlated with increased coreceptor protein levels, we per-
formed antibody detection of GAS1, BOC, and CDON in pancre-
atic tissue (Figure S1). Consistent with our gene-expression
data, we detected limited stromal expression of GAS1, BOC,Cand CDON in the normal pancreas and increased coreceptor
expression in the stroma surrounding PanIN lesions (Figure S1A).
These data suggest that GAS1, BOC, and CDON are expressed
in a population of stromal cells in the adult pancreas that ex-
pands greatly during PanIN formation.
To identify the specific cell type within the stroma expressing
these coreceptors, we performed antibody staining of tissue
from PanIN-bearing KC;Gas1LacZ/+ pancreata (Figures 1C
and S1B). Gas1LacZ expression was excluded from epithelial
(E-cadherin+) and hematopoeitic (CD45+) cells (Figure 1C, white
arrows). Similarly, b-galactosidase (b-gal) was not detected in
endothelial cells lining the blood vessels. In contrast, we de-
tected widespread coexpression of b-gal with smooth muscle
actin (SMA), a marker of activated fibroblasts (Figure 1C, yellow
arrows), throughout the stroma, except immediately surrounding
blood vessels (Figure S1B). Gas1 expression in fibroblasts was
confirmed by costaining with antibodies directed against b-gal
and vimentin, another fibroblast marker (Sugimoto et al.,
2006). We also performed antibody staining of tissue from
PanIN-bearing KC;BocPLAP/+ pancreata (Figure S1C). Antibody
detection of alkaline phosphatase (AP) colocalized with SMA,
suggesting thatGas1 andBocwere coexpressed in a population
of fibroblasts in the pancreas. In contrast, no colocalization of AP
with either E-cadherin or CK19, both epithelial markers, was
observed (Figure S1C). Thus, Boc expression was confined
to the mesenchymal compartment. Finally, we performed qRT-
PCR analysis of primary mouse pancreatic tumor cells, fibro-
blasts, and flow-sorted macrophages from the Pft1a-Cre;LSL-
KrasG12D;p53R172H/+(KPC) (Hingorani et al., 2005) and iKras
(Collins et al., 2012) pancreatic cancer models. We detected
expression of Sonic HH ligand (Shh) only in the tumor cells (Fig-
ure S1D), whereas only fibroblasts expressedGas1 (Figure S1E).
Two alternative models could explain the increase in Gas1,
Cdon, and Boc expression in the neoplastic pancreas—
increased expression on a per cell basis or increased expression
due to increased numbers of fibroblasts expressing these core-
ceptors. To distinguish between these two possibilities, we
normalized the expression of the coreceptors to the mesen-
chymal marker vimentin. Using this approach, we observed no
change in Gas1, Cdon, and Boc expression in the neoplastic
pancreas compared to control (Figure S1F). Thus, the increase
in coreceptor expression is caused by an increase in the number
of coreceptor-expressing cells within the tissue.
To determine whether our findings were relevant to human
samples, we performed qRT-PCR on resected human pancre-
atic cancer samples and adjacent uninvolved pancreas. Upre-
gulation of all three coreceptors was detected in the tumor
samples (Figure S1G). To determine which compartment ex-
pressed the coreceptors, we obtained RNA from primary human
tumor cells and primary human cancer-associated fibroblasts
(CAFs). We found elevated coreceptor expression in the CAF
population, but not in the tumor cells (Figure S1H). As expected,
VIMENTIN and E-CADHERIN were restricted to the CAF and tu-
mor compartments, respectively, thus confirming the identity of
the samples (Figure S1I). These data suggest that upregulation
of HH coreceptors is a phenomenon observed in human
pancreatic cancer and recapitulated in mouse models of this
disease.ell Reports 9, 484–494, October 23, 2014 ª2014 The Authors 485
Figure 1. Gas1, Boc, and Cdon Are Expressed in the Normal and Neoplastic Pancreas
(A) qRT-PCR analysis forGas1, Boc, and Cdon in control (n = 3), acute pancreatitis (n = 4), and KC pancreata (n = 5). The data are expressed as the mean ± SEM.
(B) Schematic ofGas1 and Boc reporter strains and KCmodel (left). Beta-galactosidase (b-gal) and alkaline phosphatase (AP) staining forGas1 and Boc reporter
expression in normal and neoplastic pancreata (right). The scale bars represent 50 mm.
(C) Antibody detection of b-gal (green) and CD45/E-cadherin (red/magenta), CD31 (magenta), SMA (red), and vimentin (red) in KC and KC;Gas1LacZ/+ PanIN
lesions. DAPI (blue) marks nuclei. White arrows (left) indicate separate b-gal and CD45 expression; yellow arrows (right) indicate coexpression of b-gal with SMA
and vimentin. The scale bar represents 20 mm.
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Together, these data demonstrate that Gas1, Boc, and Cdon
are expressed in fibroblasts in both normal and PanIN-bearing
pancreata and that their expression increases during pancre-
atic tumorigenesis as activated fibroblasts accumulate in the
pancreas. Notably, this expression pattern resembles that
observed for Ptch1 in KC mice (Tian et al., 2009), thus placing
these coreceptors in the same cell population previously re-
ported to respond to HH signaling in pancreatic cancer.
GAS1 and BOC Mediate HH Responsiveness in
Pancreatic Fibroblasts
GAS1, BOC, and CDON promote HH signaling in the developing
neural tube in a ligand-dependent manner (Allen et al., 2011). To
determine whether these coreceptors are required to transduce
HH signals in fibroblasts, we generated wild-type and Gas1/;
Boc/ mouse embryonic fibroblasts (MEFs) and treated them
withcontrolorSHHconditionedmedium.Thecellswereharvested
48 hr after treatment and analyzed for HH target gene expression
(Gli1 and Ptch1). We found significantly attenuated, although
measurable, levels of Ptch1 and Gli1 expression in Gas1/;
Boc/ fibroblasts compared towild-typecells (Figure2A). Activa-
tion of HH signaling in fibroblasts has been reported to promote
tumor growth in cotransplantation experiments (Yauch et al.,
2008). Thus, we predicted thatGas1/;Boc/ fibroblasts would
display reduced tumor-promoting ability compared to wild-type
cells. To test this hypothesis, we coinjected the human pancreatic
cancer cell lines Hs766T and MiaPaCa with either wild-type or
Gas1/;Boc/MEFs in immune-compromisedmice (Figure2B).
Surprisingly, tumor cells coinjected with Gas1/;Boc/ MEFs
grew significantly larger than tumor cells injected alone or coin-
jected with wild-type fibroblasts (Figures 2C, 2D, and S2A).
Analysis of these tumors revealed comparable epithelial histology
for all experimental cohorts, including the accumulation of
a collagen-rich stroma (Figure 2C, inset). However, blood vessel
density was dramatically increased in tumors coinjected with
Gas1/;Boc/ fibroblasts compared to tumor cells alone or
coinjected with wild-type fibroblasts (Figures 2C and 2E).
To study this phenomenon in a more physiologically relevant
system, we performed a similar experiment with primary human
pancreatic cancer cells (1319; Li et al., 2007; Zhang et al., 2013)
and primary pancreatic fibroblasts isolated from either wild-
type or Gas1/;Boc/ embryonic day 18.5 (E18.5) mouse em-
bryos (Figure 2F). Despite the perinatal lethality of Gas1/;
Boc/ embryos (Allen et al., 2011), histological analysis of
E18.5 pancreata revealed no gross abnormalities (data not
shown). To assess HH responsiveness, we treated wild-type
and Gas1/;Boc/ pancreatic fibroblasts with control or
SHH-conditioned media and extracted RNA 24 hr later. Similar
to the MEF lines, SHH treatment induced robust expression of
both Gli1 and Ptch1 in wild-type pancreatic fibroblasts,
whereas this response was significantly attenuated in Gas1/;
Boc/ pancreatic fibroblasts (Figure 2F). Thus, HH corecep-
tors are required for normal HH signaling in both MEFs and
pancreatic fibroblasts.
We then coinjected 1319 cells alone or in combination with
either genotype of pancreatic fibroblasts into mice. Notably,
1319 cells express SHH in culture at levels comparable to
Hs766T cells (Figure S2B). Injection of 1319 cells alone formedCsubcutaneous tumors that were larger upon coinjection with
wild-type fibroblasts, as expected (Figure 2H; Yauch et al.,
2008). However, coinjection with Gas1/;Boc/ pancreatic fi-
broblasts resulted in even larger tumors (Figure 2H). Tumor his-
tology from each cohort was similar as assessed by hematoxylin
and eosin (H&E) and Gomori staining, with a marked ductal
morphology and abundant stroma, thus resembling the most
common histology of human pancreatic cancer (Figure 2G; Col-
lisson et al., 2011). However, CD31 immunostaining revealed a
dramatic increase in vasculature within tumors coinjected with
Gas1/;Boc/ pancreatic fibroblasts (Figures 2G and 2I). The
Gas1/;Boc/ fibroblasts were detected in close association
with blood vessels, as determined by b-gal immunostaining (Fig-
ure 2G). Thus, stromal deletion of Gas1 and Boc results in atten-
uated HH responsiveness that paradoxically increases tumor
growth. Given the heterogeneity of stromal fibroblasts (Sugimoto
et al., 2006), these Gas1- and Boc-expressing fibroblasts may
represent a subset of cells in which HH ligands inhibit an angio-
genic response.
Dosage-Dependent Stromal HH Signaling Differentially
Promotes Pancreatic Tumor Growth
Our data contrast with previous studies in which SMO blockade
in the stroma inhibits pancreatic tumor growth (Olive et al.,
2009; Yauch et al., 2008). Notably, despite the significantly
reduced response toHHsignaling inGas1/;Boc/ fibroblasts,
these cells are not completely refractory to HH pathway stimula-
tion (Figures 2A and 2F). One possibility is that the level of HH
pathway activation differentially affects pancreatic tumor growth.
Tounderstand the relationshipbetweenHHsignalingdosageand
tumor promotion, we generatedGas1/Boc/;Cdon/MEFs.
Of note, we could not use pancreatic fibroblasts as triple-null em-
bryos die at E9.5 (Allen et al., 2011) at the onset of pancreas
development. Gas1/Boc/;Cdon/ MEFs had nearly unde-
tectable activation of HH target genes when exposed to
SHH-conditioned medium (Figure 3A). We cotransplanted 1319
tumor cells alone or with three different cohorts of MEFs: wild-
type, Gas1/Boc/, and Gas1/Boc/;Cdon/ (Figure 3B).
Again, wild-type MEFs promoted tumor growth compared to
tumor cells alone and Gas1/Boc/ MEFs promoted tumor
growth further (Figure 3C). In contrast, tumors coinjected with
Gas1/;Boc/;Cdon/MEFswerecomparableboth in growth
rate and size at dissection to tumor cells alone (Figures 3C and
3D). These data are consistent with the reduced tumor-promot-
ing ability of Smo/ MEFs that are refractory to HH stimulation
(Yauch et al., 2008). Whereas cell death was similar in all experi-
mental cohorts, we detected increased intratumoral proliferation
in coinjections with tumor cells and Gas1/Boc/ MEFs; this
effect was abrogated in coinjections with Gas1/;Boc/;
Cdon/ MEFs (Figure S3A). To verify that the coinjected MEFs
persisted within the tumor at the time of analysis, we took advan-
tage of lineage tracing provided by the expression of the b-gal re-
porter from the Gas1 locus in these cells. By b-gal staining and
quantitation, we detected that both double and triple knockout
cells were present within the tumors (Figures 3E and S3B).
Although tumor size varied between the different experi-
mental groups, the histology was similar, with ductal structures
surrounded by collagen-rich stroma (Figure 3E). Notably, theell Reports 9, 484–494, October 23, 2014 ª2014 The Authors 487
Figure 2. Stromal Deletion of Gas1 and Boc Impairs HH Responsiveness but Promotes Tumor Growth
(A) qRT-PCR analysis of Gli1 and Ptch1 in MEFs.
(B) Schematic of subcutaneous tumor injection experiment.
(legend continued on next page)
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level of SHH ligand produced by the tumor cells (detected with
human-specific primers and normalized to human
CYCLOPHILIN) did not change among the different groups (Fig-
ure S3C). Genetic inactivation of Shh in multiple mouse models
of pancreatic cancer resulted in variable reduction of stroma
accumulation in different settings (Dai et al., 1999; Lee et al.,
2014). To further investigate potential changes to the stroma
in our model, we quantified the relative ratio of mesenchymal
cells within the tumors (identified by immunostaining for vimen-
tin) and observed no measurable change (Figures S3A and
S3D). Furthermore, qRT-PCR analysis for collagen I revealed
no difference among the different cohorts (Figure S3E), indi-
cating no changes in fibrosis. The differences between the
two models might derive from the different timing of HH
pathway alteration. Interestingly, analysis of pre- and posttreat-
ment biopsies of liver metastases in a recent clinical trial of the
HH inhibitor GDC-0449 revealed only a mild reduction of
fibrosis in half the patients and no changes in fibrosis in the
other half, consistent with our findings (D. Simeone, personal
communication).
Whereas the accumulation of fibroblasts within the stroma
did not change, the number of blood vessels was significantly
increased in tumors coinjected with Gas1/Boc/ MEFs,
but not in tumors coinjected with Gas1/;Boc/;Cdon/
MEFs compared with control, as quantified by CD31 immuno-
staining (Figures 3E and 3F). A similar increase in vasculature
was previously observed following genetic ablation of Shh or
following drug-mediated inhibition of SMO, although the
mechanism remained to be investigated (Dai et al., 1999;
Lee et al., 2014; Olive et al., 2009). Thus, reduced HH
response promotes tumor vascularity and growth, whereas
complete HH pathway blockade fails to promote tumor
growth (Figure 3G).
Reduced HH Signaling Promotes Angiogenesis
To determine the mechanism by which reduced HH signaling
promotes tumor growth and vascularity, we measured the
expression of several angiogenic factors by qRT-PCR (Figures
4A and 4B). Along with VEGFa, the angiopoietins (ANGPT1 and
ANGPT2) encompass a family of factors that act on the vascular
endothelium (Augustin et al., 2009). In bothGas1/Boc/MEFs
and pancreatic fibroblasts, Angpt2 was upregulated compared
to control pancreatic fibroblasts and MEFs, respectively; in
contrast, Angpt2 expression in Gas1/;Boc/;Cdon/ MEFs
was comparable to wild-type MEFS (Figures 4A and 4B). The
expression of other angiogenic factors varied between MEFs
and pancreatic fibroblasts, although in all cases, reduced HH
signaling resulted in increased expression of angiogenic factors,(C) Histopathological analysis of tumors following coinjection of Hs766T cells with
H&E staining (left) and Gomori trichrome (inset, left). Antibody detection of b-gal
(D) Quantitation of final tumor size.
(E) Quantitation of CD31 staining.
(F) Schematic of pancreatic fibroblast isolation. qRT-PCR analysis of Gli1 and P
(G) Histopathological analysis of tumors following coinjection of 1319 cells with
represents 20 mm. Antibody detection of b-gal (green) and CD31 (red; right). DAP
(H and I) Quantitation of (H) final tumor size and (I) CD31 staining. The data are ex
follows: *p < 0.05; **p < 0.01; ***p < 0.0005; ****p < 0.0001.
Cwhereas the abrogation of HH signaling inhibited angiogenic
gene expression (Figures 4A and 4B). For example, Angpt1
expression was significantly upregulated in Gas1/;Boc/
pancreatic fibroblasts (Figure 4A), whereas VEGFa, previously
described as a HH target in stromal perivascular cells (Chen
et al., 2011), was upregulated in Gas1/;Boc/ MEFs (Fig-
ure 4B). The specific gene programs activated were not identical,
possibly indicating distinct properties of fibroblasts of different
origins.
To determine whether the change in expression of the angio-
genic factors depended on ligand-mediated HH signaling, we
treated wild-type or Gas1/Boc/ pancreatic fibroblasts
with control-conditioned medium or SHH-conditioned medium.
SHH treatment induced expression of Vegfa and Angpt1 while
repressing expression of Angpt2 (Figure S4A) consistent with
previous publications (Lee et al., 2007; Chen et al., 2011).
The induction of Vegfa and overall expression levels were
similar in Gas1/Boc/ pancreatic fibroblasts. In contrast,
both Angpt1 and Angpt2 had higher basal expression levels
in Gas1/Boc/ pancreatic fibroblasts, but the extent of rela-
tive induction or repression in response to SHH was reduced in
comparison to wild-type fibroblasts, indicating that both
ligand-dependent and ligand-independent mechanisms regu-
lated the expression of these angiogenic factors (Figures S4A
and S4B).
To further dissect the angiogenic properties of fibroblasts lack-
ing Gas1 and Boc, we used the chick chorioallantoic membrane
(CAM) assay. Gas1/;Boc/ pancreatic fibroblasts and MEFs
implanted alone atop the CAM induced the formation of more
blood vessels than wild-type MEFs. Notably, this proangiogenic
effect was not detected in Gas1/;Boc/;Cdon/ MEFs
(Figure S4C).
We next coimplanted 1319 tumor cells with wild-type or
Gas1/;Boc/ pancreatic fibroblasts. Wild-type fibroblasts
promoted tumor growth inCAMassays, in agreementwith our ob-
servations in the mouse (Figure 4C). Again, Gas1/;Boc/
pancreatic fibroblasts promoted the growth of even larger,
more-vascularized tumors (Figures 4C and 4D). Similar results
were obtained using a primary mouse pancreatic cancer cell line
(Zhang et al., 2013) derived from the KPC (Hingorani et al., 2005)
pancreatic cancer model (Figure S4D).
We then tested Gas1/;Boc/;Cdon/ MEFs in this assay
and observed reduced tumor growth and vascularization (Fig-
ures 4E and 4F), indicating that tumor promotion and angiogen-
esis are specifically linked to the degree of HH responsiveness.
Similar to the subcutaneous tumor injections, Gas1/;Boc/;
Cdon/ fibroblasts did not impact tumor growth compared to
tumor cells alone (Figure 4F).MEFs. The scale bar represents 50 mm and inset scale bar represents 50 mm.
(green) and CD31 (red; right). DAPI (blue) marks nuclei.
tch1.
pancreatic fibroblasts. The scale bar represents 20 mm and inset scale bar
I (blue) marks nuclei.
pressed as the mean ± SEM. Significance values indicated by asterisks are as
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(legend on next page)
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SIGNIFICANCE
The Hedgehog coreceptors Gas1, Cdon, and Boc are required
to mediate HH signaling during embryonic development (Allen
et al., 2011), but their potential role in adult tissues and in dis-
ease remained largely unexplored. Here, we show that these
coreceptors are expressed in pancreatic cancer and modulate
the levels of HH responsiveness in pancreatic fibroblasts.
Despite initial expectations that fibroblasts with reduced HH
responsiveness would be impaired in their ability to support
tumor growth, surprisingly we found that these cells promoted
tumor growth to a significantly greater extent than wild-type fi-
broblasts. Although HH-pathway inhibition showed promise in
mouse models of pancreatic cancer (Olive et al., 2009), clinical
trials in humans were unsuccessful (Amakye et al., 2013). Treat-
ment with HH inhibitors in human patients are likely to result in
a strong reduction, but not complete inactivation, of HH
signaling, because the drugs are continuously metabolized
and excreted in between doses. Here, we show that HH dosage
is a key consideration in cancer treatment, where reduced
levels of HH signaling evoke a potent angiogenic response.
Thus, an angiogenic response might constitute a clinical
readout of successful but partial HH blockade in vivo. Whereas
dosage-specific HH response has not been considered in can-
cer, developmental biology provides ample evidence of HH
target genes activated at specific thresholds of signaling (for re-
view, see Jessell, 2000). Further, although angiogenic blockade
has not been used in pancreatic cancer due to its hypovascu-
larity, our results raise the possibility that HH pathway blockade
in pancreatic cancer may render tumors susceptible to antian-
giogenic therapy. A recent study indicates a possible benefit
of this combination therapy on a mesenchymal subtype of
pancreatic cancer in genetically engineered mice (Rhim et al.,
2014). Whether the failure of the recent HH inhibition trials in
pancreatic cancer are due to an increase in angiogenesis
should be investigated.
Another aspect of interest is the finding that MEFs and
pancreatic fibroblasts have differences in HH-mediated gene
regulation. The differences among fibroblasts populations in
different organs are poorly understood and might play an
important role in cancer treatment, as fibroblasts at the
metastatic sites might respond differently to treatment
compared to fibroblasts at the primary site. HH signaling has
been associated with pancreatic cancer metastasis (Feldmann
et al., 2007), indicating the need for further studies aimed at
characterizing HH response in fibroblasts derived from the
pancreas and from common metastatic sites (such as liver
and lung).Figure 3. Dosage-Dependent HH Signaling Differentially Promotes Pan
(A) qRT-PCR analysis for Gli1 and Ptch1 in MEFs.
(B) Schematic of subcutaneous tumor injection experiment.
(C) Growth curve for subcutaneous tumors.
(D) Quantitation of final tumor size.
(E) Histopathological analysis of tumors following coinjection of 1319 cells with ME
staining (top) and Gomori trichrome (inset, top). Antibody detection of b-gal (gre
(F) Quantitation of CD31 staining.
(G) Comparison of tumor size and vascularity between fibroblast lines. The data ar
as follows: *p < 0.05; **p < 0.01; ***p < 0.0005; ****p < 0.0001.
CEXPERIMENTAL PROCEDURES
Mice
Mice were housed in specific pathogen-free facilities of the University of
Michigan Comprehensive Cancer Center. This study was approved by the
University of Michigan University Committee on Use and Care of Animals
guidelines. Ptf1a-Cre mice (Kawaguchi et al., 2002) were intercrossed with
LSL-KrasG12D (Hingorani et al., 2003) to generate KC animals. KC mutant
mice were further crossed with mice bearing reporter alleles Gas1LacZ/+
(Martinelli and Fan, 2007) or BocAP/+ (Zhang et al., 2011) to generate
KC;Gas1LacZ/+ or KC;BocAP/+. Acute pancreatitis was induced by two 8-
hourly series of intraperitoneal injections with caerulein (Sigma-Aldrich) at a
concentration of 75 mg/kg over a 48 hr period, as previously described (Mor-
ris et al., 2010).
Cell Culture
Primary mouse pancreatic fibroblast lines were derived from E18.5 wild-type
orGas1/;Boc/ pancreata. Embryonic pancreata wereminced via vigorous
pipetting and then immediately plated. MEFs were isolated and established
using the methods of Todaro and Green (1963). Samples were cultured in
Iscove’s modified Dulbecco’s medium (IMDM) supplemented with 10% fetal
bovine serum and 1% penicillin/streptomycin (GIBCO). For HH-signaling
assays, plated cells were serum-starved (IMDM supplemented with 0.5%
serum) for 36 hr prior to addition of conditioned media and samples collected
at indicated time points.
Statistical Analysis
The data are expressed as the mean ± SEM. One-way ANOVA with
a Tukey posttest and Student’s t tests were used to compare data. A
p value <0.05 was considered statistically significant. Significance values
indicated by asterisks are as follows: *p < 0.05, **p < 0.01, ***p < 0.0005,
and ****p < 0.0001.
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